Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2020-09-07
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to evaluate the safety and efficacy of capmatinib in
combination with spartalizumab in adult participants with epidermal growth factor receptor
(EGFR) wild type (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic
lymphoma kinase (ALK) rearrangement negative in locally advanced (stage IIIB, not eligible
for definitive chemo-radiation) or metastatic (stage IV) Non-small cell lung cancer (NSCLC)
after failure of platinum doublet and checkpoint inhibitor treatment.